LianBio (LIANY)

Market Cap	21.63M
Revenue (ttm)	n/a
Net Income (ttm)	-87.98M
Shares Out	108.17M
EPS (ttm)	-0.82
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Average Volume	6,511
Open	0.1743
Previous Close	0.2000
Day's Range	0.2000 - 0.2000
52-Week Range	0.1740 - 0.3720
Beta	0.03
RSI	53.00
Earnings Date	Mar 27, 2025

About LianBio

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatme...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2019
• Employees: 163
• Stock Exchange: OTCMKTS
• Ticker Symbol: LIANY